Rapport Therapeutics (NASDAQ:RAPP) Short Interest Update

Rapport Therapeutics (NASDAQ:RAPP) was the target of a significant decline in short interest during the month of November. As of November 15th, there was short interest totalling 1,740,000 shares, a decline of 17.5% from the October 31st total of 2,110,000 shares. Based on an average daily trading volume, of 147,800 shares, the short-interest ratio is currently 11.8 days. Approximately 10.0% of the company’s shares are short sold.

Rapport Therapeutics Stock Up 2.0 %

Shares of RAPP stock traded up $0.45 during mid-day trading on Friday, hitting $22.84. 30,110 shares of the company’s stock were exchanged, compared to its average volume of 154,769. The company has a 50-day simple moving average of $23.12. Rapport Therapeutics has a fifty-two week low of $16.55 and a fifty-two week high of $29.74.

Institutional Investors Weigh In On Rapport Therapeutics

Several hedge funds have recently modified their holdings of the stock. Values First Advisors Inc. purchased a new stake in Rapport Therapeutics during the third quarter valued at about $31,000. BNP Paribas Financial Markets purchased a new stake in shares of Rapport Therapeutics during the 3rd quarter worth about $34,000. SG Americas Securities LLC acquired a new stake in Rapport Therapeutics during the 3rd quarter worth approximately $101,000. Sandia Investment Management LP purchased a new position in Rapport Therapeutics in the second quarter valued at approximately $116,000. Finally, MetLife Investment Management LLC acquired a new position in Rapport Therapeutics during the third quarter valued at approximately $117,000.

About Rapport Therapeutics

Rapport Therapeutics Inc is a clinical-stage biotechnology company. It focused on discovery and development of transformational small molecule medicines for patients suffering from central nervous system disorders. Rapport Therapeutics Inc is based in BOSTON.